Evaluation of the effect of piperine per se on blood glucose level in alloxan-induced diabetic mice

Acta Poloniae Pharmaceutica - Drug Research

Volumn 69, Issue 5, 2012, Pages 965-969

  Atal, Shubham ^a   Agrawal, Rajendra P ^a   Vyas, Savita ^a   Phadnis, Pradeep ^a   Rai, Niket ^a  

^a MGM MEDICAL COLLEGE   (India)

Author keywords

Albino mice; Alloxan; Diabetes; Metformin; Piperine

Indexed keywords

ALLOXAN; GLUCOSE; GUM ARABIC; METFORMIN; PIPERINE;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ISOLATION; DRUG MEGADOSE; DRUG SCREENING; DRUG STRUCTURE; GLUCOSE BLOOD LEVEL; MALE; MOUSE; NONHUMAN; THERAPY EFFECT;

ALKALOIDS; ANIMALS; BENZODIOXOLES; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED NOD; PIPER NIGRUM; PIPERIDINES; PLANT EXTRACTS; POLYUNSATURATED ALKAMIDES;

EID: 84866003123     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. th edn., pp. 805-847, Elsevier, London 2006.
2. David S.H., Bell M.B.: South. Med. J. 95, 24 (2002).
3. Saxena A., Vikram N.K.: J. Altern. Complement. Med. 10, 369 (2004).
4. Panda S., Kar A.: Horm. Metab. Res. 35, 523 (2003).
5. Johri R.K., Zutshi U.: J. Ethnopharmacol. 37, 851(1992).
6. Li S., Wang C., Wang M., Li W., Matsumoto K., Tang Y.: Life Sci. 80, 1373 (2007).
7. Wang L., Zhao D., Zhang Z., Zuo C., Zhang Y., Pei Y.Q., Lo Y.Q.: Brain Dev. 21, 36 (1999).
8. Rauscher F.M., Sanders R.A., Watkins J.B. III.: J. Biochem. Mol. Toxicol. 14, 329 (2000).
9. Prakash UN, Srinivasan K.: Appl. Physiol. Nutr. Metab. 35, 134 (2010).
10. El Hamss R., Idaomar M., Alonso-Moraga A., Muñoz Serrano A.: Food Chem. Toxicol. 41, 41 (2003).
11. Matsuda H., Ninomiya K., Morikawa T., Yasuda D., Yamaguchi I., Yoshikawa M.: Bioorg. Med. Chem. Lett. 18, 2038 (2008).
12. Vijayakumar RS, Nalini N.: J. Basic Clin. Physiol. Pharmacol. 17, 71 (2006).
13. th edn., p 143, Vallabh Prakashan, New Delhi 2003.
14. th edn., p. 1286, Merck & Co., Whitehouse Station, NJ 1996.
15. Oladiende F.O., Kinyua A.M., Laditan A.A., Michelin R., Bryant J.L., Denaro F. et al.: Cell. Mol. Biol. 53, 34 (2007).
16. Ezeigbo II.: Int. J. Diab. Dev. Ctries. 30, 150 (2010).
17. Majeed M. et al.: Use of piperine as a bioavailability enhancer. U.S. Patent 5744161. April 28, 1998.
18. rd edn., Table 20, 2, Sinauer Associates, Sunderland, MA 2004.
19. Trovik T.S., Vaartun A., Jorde R., Sager G.: Eur. J. Clin. Pharmacol. 48, 327 (1995).
20. th edn., p. 163, Churchill Livingstone, Edinburgh, UK 2003.
21. Klein J., Fasshauer M., Benito M., Kahn C.R.: Mol. Endocrinol. 14, 764 (2000).
22. st edn., p. 653, Paras Medical Publishers, New Delhi 2008.